A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects - Trial 2012-000299-40
Access comprehensive clinical trial information for 2012-000299-40 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma Services AG and is currently status unknown. The study focuses on Healthy volunteers.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2012-000299-40
Trial Details
EU Clinical Trials Register • 2012-000299-40
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects
Study Focus
Sponsor & Location
Novartis Pharma Services AG
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Primary pharmacokinetic parameters: AUC(0-t), AUC(0-inf) and Cmax
ICD-10 Classifications
Healthy person accompanying sick person
Routine general health check-up of armed forces
Routine general health check-up of sports teams
Routine general health check-up of inhabitants of institutions
Data Source
EU Clinical Trials Register
2012-000299-40
Non-Device Trial